Your browser doesn't support javascript.
loading
A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.
Sutton, Selina K; Carter, Daniel R; Kim, Patrick; Tan, Owen; Arndt, Greg M; Zhang, Xu Dong; Baell, Jonathan; Noll, Benjamin D; Wang, Shudong; Kumar, Naresh; McArthur, Grant A; Cheung, Belamy B; Marshall, Glenn M.
Afiliação
  • Sutton SK; Children's Cancer Institute for Medical Research, Lowy Cancer Research Centre, University of New South Wales, New South Wales, Australia.
  • Carter DR; School of Women's and Children's Health, University of New South Wales Australia, New South Wales, Australia.
  • Kim P; Children's Cancer Institute for Medical Research, Lowy Cancer Research Centre, University of New South Wales, New South Wales, Australia.
  • Tan O; School of Women's and Children's Health, University of New South Wales Australia, New South Wales, Australia.
  • Arndt GM; Children's Cancer Institute for Medical Research, Lowy Cancer Research Centre, University of New South Wales, New South Wales, Australia.
  • Zhang XD; School of Women's and Children's Health, University of New South Wales Australia, New South Wales, Australia.
  • Baell J; Children's Cancer Institute for Medical Research, Lowy Cancer Research Centre, University of New South Wales, New South Wales, Australia.
  • Noll BD; Children's Cancer Institute for Medical Research, Lowy Cancer Research Centre, University of New South Wales, New South Wales, Australia.
  • Wang S; Priority Research Centre for Cancer Research Oncology and Immunology Unit, University of Newcastle, New South Wales, Australia.
  • Kumar N; Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Monash Institute of Pharmaceutical Sciences, Monash University, Victoria, Australia.
  • McArthur GA; Centre for Drug Discovery and Development, Sansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, South Australia, Australia.
  • Cheung BB; Centre for Drug Discovery and Development, Sansom Institute for Health Research and School of Pharmacy and Medical Sciences, University of South Australia, South Australia, Australia.
  • Marshall GM; School of Chemistry, University of New South Wales Australia, New South Wales, Australia.
Oncotarget ; 7(32): 52166-52178, 2016 Aug 09.
Article em En | MEDLINE | ID: mdl-27447557
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Benzimidazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Ligação a DNA / Melanoma Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Benzimidazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Ligação a DNA / Melanoma Idioma: En Ano de publicação: 2016 Tipo de documento: Article